References
- Jung E. G. Xeroderma pigmentosum: heterogeneous syndrome and model for UV carcinogenesis. Bull Cancer 1978; 65: 315–21
- Kraemer K. H., Levy D. D., Parris C. N., Gozukara E. M., Moriwaki S., Adelberg S., et al. Xeroderma pigmentosum and related disorders: examining the linkage between defective DNA repair and cancer. J Invest Dermatol 1994; 103: S96–101
- Miyauchi H., Tanaka K., Horio T. Enhanced inflammation and immunosuppression by ultraviolet radiation in xeroderma pigmentosum group A (XPA) model mice. J Invest Dermatol 1996; 107: 343–8
- Fraitag S. Melanocytic nevi in children. Ann Pathol 2004; 24: 587–604
- Roseeuw D. The treatment of basal skin carcinomas in two sisters with xeroderma pigmentosum. Clin Exp Dermatol 2003; 28((suppl 1))30–2
- DiGiovanna J. J. Retinoid chemoprevention in patients at high risk for skin cancer. Med Pediatr Oncol 2001; 36: 564–7
- Barbara A. G., Eller S. M., Geller A. C., Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999; 340: 1341–8
- Khatri M. L., Shafi M., Machina A. Xeroderma pigmentosum – a clinical study of 24 Libyan cases. J Am Acad Dermatol 1992; 26: 75–8
- Malvehy J., Puig S., Marti‐Laborda R. M. Dermoscopy of skin lesions in two patients with xeroderma pigmentosum. Br J Dermatol. Williams & Wilkins Publication 2005; 152: 271–8
- Mallory S. Xeroderma pigmentosum. Disorders with malignant potential: genodermatoses, J. L Spitz, 1995; 152–5, Williams & Wilkins
- Kraemer K. H., Lee M. M., Scotto J. Xeroderma pigmentosum: cutaneous, ocular and neurologic abnormalities in 830 published cases. Arch Dermatol 1987; 123: 241–50
- Fearon E. R. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997; 278: 1043–50
- Somos S., Farkas B., Schneider I. Cancer protection in xeroderma pigmentosum variant (XP‐V). Anticancer Res 1999; 19(3B): 2195–9
- Akyol M., Ozcelik S. Non‐acne dermatologic indications for systemic isotretinoin. Am J Clin Dermatol 2005; 6: 175–84
- Fine J. D., Johnson L. B., Weiner M., Stein A., Suchindran C. Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: results of Phase 1 trial of systemic isotretinoin. J Am Acad Dermatol 2004; 50: 563–71
- Kraemer K. H., DiGiovanna J. J., Moshell A. N., Tarone R. E., Peck G. L. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318: 1633–7
- Moriwaki S., Kraemer K. H. Xeroderma pigmentosum – bridging a gap between clinic and laboratory. Photodermatol Photoimmunol Photomed 2001; 17: 47–54
- Lambert W. C., Kuo H., Lambert M. W. Xeroderma pigmentosum. Dermatol Clin 1995; 13: 169–209